文献速递肾移植

SGLT2抑制剂在肾移植受者中的疗效、机制与安全性:随机双盲安慰剂对照试验

Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-12-12

该随机双盲安慰剂对照试验纳入52例肾移植受者,评估达格列净10mg每日一次治疗12周的生理效应。主要目的是评估降压效果,结果显示达格列净未降低收缩压,但1周后降低平均动脉压3.9 mmHg,并显著降低Iohexol测量的GFR(1周降低4.2 ml/min/1.73m²,12周降低3.49 ml/min/1.73m²),增加尿糖,安全耐受良好。

要点

  • 达格列净未显著降低肾移植受者收缩压,但1周时平均动脉压降低3.9 mmHg。
  • 达格列净显著降低Iohexol测量的GFR,1周降低4.2,12周降低3.49 ml/min/1.73m²。
  • 达格列净增加尿糖,未改变近端钠处理,安全耐受良好,无尿路感染。

核心结论

  • 达格列净在肾移植受者中激活了预期的生理通路,但关键差异提示其机制可能与非移植人群存在异质性。
  • 需要临床结局试验来确定这些机制效应能否转化为肾脏和心血管结局的改善。

研究设计与样本

  • 在钳夹正常血糖(4-6 mmol/L)条件下,于基线、治疗1周和12周进行三次序贯生理评估。

主要发现

  • 与安慰剂相比,达格列净未降低1周或12周时的收缩压,但1周时降低平均动脉压3.9 mmHg(95%CI -7.5至-0.2)。
  • 达格列净导致Iohexol测量的GFR从基线至1周显著降低4.2 ml/min/1.73m²(95%CI -7.14至-1.24),至12周降低3.49 ml/min/1.73m²(95%CI -6.33至-0.64)。
  • 达格列净显著增加尿糖,未改变近端钠处理或交感神经激活证据。
  • 12周时达格列净组观察到动脉僵硬度急性降低(颈动脉增强指数-3.5%;95%CI -6.0至-1.1),但与安慰剂相比无统计学意义。
  • 达格列净总体安全且耐受良好,两组均未观察到尿路或生殖器感染事件。

关键数值与推荐

  • 研究纳入52例肾移植受者,平均年龄53±13岁,62%患高血压,57%患2型糖尿病,50%使用肾素-血管紧张素-醛固酮系统抑制剂,平均eGFR 68.2±24.4 ml/min/1.73m²。
  • 达格列净剂量为10 mg每日一次,治疗12周。
  • 主要目的是评估达格列净的降压效果,次要结局包括Iohexol测量的GFR、利钠、身体成分、无创心输出量监测、动脉僵硬度、心率变异性、神经激素和安全性。

临床怎么用

  • 达格列净在肾移植受者中安全耐受,可考虑用于心肾保护,但需注意其降收缩压效果不显著。
  • 使用达格列净后可能出现GFR急性下降,需监测肾功能变化。
  • 肾移植受者使用达格列净的临床获益需等待结局试验证实。

局限性

  • 样本量较小(52例),可能不足以检测收缩压等结局的显著差异。
  • 研究为生理机制评估,非临床结局试验,无法确定对肾脏和心血管结局的长期影响。
  • 随访时间仅12周,长期安全性和疗效未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: The effIcacy, mechaNisms and saFety of SGLT2 INhibitors in kIdney Transplant recIpients trial assessed the physiologic effects of sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients. In kidney transplant recipients, sodium-glucose cotransporter-2 inhibitors lowered mean arterial pressure after 1 week, reduced GFR, increased glucosuria, and were safe. Dapagliflozin was well tolerated in kidney transplant recipients, showing similar cardio-kidney effects seen in other groups; outcome trials in kidney transplant recipients are now needed. BACKGROUND: Cardiovascular and kidney protective mechanisms with 12 weeks of sodium-glucose cotransporter-2 inhibitor treatment (dapagliflozin 10 mg daily) were assessed in kidney transplant recipients (KTR) with and without type 2 diabetes. METHODS: This randomized double-blind, parallel-group, placebo-controlled study enrolled 52 KTR and comprised three sequential physiologic assessments under clamped euglycemia (4-6 mmol/L): baseline, at 1, and 12 weeks of treatment. The primary objective was to evaluate BP lowering with dapagliflozin. Secondary outcomes were iohexol-measured GFR, natriuresis, body composition, noninvasive cardiac output monitoring, arterial stiffness, heart rate variability, neurohormones, and safety. RESULTS: Fifty-one KTR completed the study-mean age 53±13 years, 62% with hypertension, 57% with type 2 diabetes, 50% on renin-angiotensin-aldosterone system inhibitors, and mean eGFR 68.2±24.4 ml/min per 1.73 m 2 . Compared with placebo, dapagliflozin did not lower systolic BP at 1 or 12 weeks, although it did reduce mean arterial pressure after 1 week (3.9 mm Hg; 95% confidence interval [CI], -7.5 to -0.2). Dapagliflozin led to significant, placebo-adjusted reductions in iohexol-measured GFR from baseline to 1 week (4.2 ml/min per 1.73 m 2 ; 95% CI, -7.14 to -1.24 ml/min per 1.73 m 2 ) and 12 weeks (-3.49 ml/min per 1.73 m 2 ; 95% CI, -6.33 to -0.64). Dapagliflozin significantly increased glucosuria without altering proximal sodium handling or evidence of sympathetic activation. Acute decreases in arterial stiffness (carotid augmentation index, -3.5%; 95% CI, -6.0 to -1.1) were observed in the dapagliflozin group after 12 weeks, although this was not significant compared with placebo. Dapagliflozin was generally safe and well tolerated. No episodes of urinary tract or genitourinary infections were observed in either treatment group throughout the trial. CONCLUSIONS: Dapagliflozin activated expected physiologic pathways, although key differences observed in KTR might suggest mechanistic heterogeneity compared with nontransplant populations. Clinical trials evaluating sodium-glucose cotransporter-2 inhibitors in KTR are important to determine whether these mechanistic effects translate to improvements in kidney and cardiovascular outcomes. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT04965935 . PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3//www.asn-online.org/media/podcast/JASN/2026_02_09_KTS_February2026.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Sridhar VS, Kugathasan L, Lytvyn Y, et al. Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin J Am Soc Nephrol. 2025. PMID: 41385300. doi:10.2215/CJN.0000000951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。